Drug Name: Epkinly

Indications: To treat relapsed or refractory diffuse large B-cell lymphoma (not otherwise specified) and high-grade B-cell lymphoma after two or more lines of systemic therapy.

Active Ingredient: Epcoritamab-bysp

Company: Genmab A/S

Approval Date: 5/19/2023

More Details: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761324s000lbl.pdf

Leave a Reply

Your email address will not be published. Required fields are marked *